Discovering a Common Goal,
Discovering a Cure

CONTACT  |  DONATE  |  E-NEWSLETTER  | 
  
DRUG NEWS

Research News
Drug News
Conference News
< Home



LRP4 Identified as Potential Serum Biomarker and Therapeutic Target in ALS
June 25, 2015

A team of researchers led by Socrates Tzartos from the Hellenic Pasteur Institute in Athens, Greece have identified antibodies to an important neuromuscular protein in the serum of twenty percent of ALS patients. The protein, called LDL...

New Findings on SOD1 Protein Properties Are Key Step in Antisense Clinical Trials
June 24, 2015

Mutations in the superoxide dismutase (SOD1) gene are the second most common cause of inherited ALS, and account for approximately 2% of ALS cases. Antisense oligonucleotides designed to reduce levels of SOD1 represent a promising therapeutic...

InVivo Therapeutics Enrolls Third Patient in Trial of Biodegradable Scaffold for Spinal Cord Injury
June 11, 2015

A third spinal cord injury patient has been enrolled inInVivo Therapeutics’pilot clinical trial testing a novel biodegradable scaffold as a therapeutic device for spinal cord injury.  The...

Q-Therapeutics Gains FDA Clearance to Initiate Clinical Trials in ALS
June 4, 2015

Salt Lake City, Utah-based Q-Therapeutics has obtained FDA clearance of its Investigational New Drug (IND) application to initiate a Phase I/II trials of their proprietary stem cell therapy in ALS patients....

Cytokinetics and the ALS Association Announce Expanded Partnership
June 4, 2015

Cytokinetics and the ALS Association (ALSA) have announced an expanded partnership to advance support services for ALS patients and caregivers and to increase disease awareness. The partnership, which...





The ALS Forum was developed by Prize4Life, Inc.
 
© 2015 Prize4Life, Inc.
Identified content provided through
a partnership with the Alzforum